ストックスクリーナーアプリを入手
16.04
4.30%
-0.72
前日終値:
$16.76
開ける：
$16.77
24時間の取引高:
398.35K
Relative Volume:
1.00
時価総額：
$5.72B
収益：
$5.10B
当期純損益:
$-352.00M
株価収益率:
-15.74
EPS:
-1.0189
ネットキャッシュフロー:
$-66.14M
1週間 パフォーマンス:
-4.01%
1か月 パフォーマンス:
+2.04%
6か月 パフォーマンス:
+2.62%
1年 パフォーマンス:
+33.11%
1日の値動き範囲:
$15.96
$16.83
1週間の範囲:
$15.96
$17.12
52週間の値動き範囲:
$10.45
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.04 | 5.72B | 5.10B | -352.00M | -66.14M | -1.0189 |
ISRG
Intuitive Surgical Inc
|
451.29 | 160.28B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.69 | 44.57B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
47.51 | 38.56B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
77.82 | 37.93B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
221.22 | 32.23B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Neutral |
| 2025-05-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-03-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 開始されました | Raymond James | Outperform |
| 2024-05-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 開始されました | Stifel | Hold |
| 2023-10-03 | 再開されました | Evercore ISI | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 開始されました | Needham | Hold |
| 2022-12-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-12 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-06-24 | 開始されました | Evercore ISI | Outperform |
| 2022-06-06 | 開始されました | Citigroup | Buy |
| 2022-05-31 | 開始されました | Deutsche Bank | Hold |
| 2022-05-31 | 開始されました | Goldman | Neutral |
| 2022-05-31 | 開始されました | Guggenheim | Buy |
| 2022-05-31 | 開始されました | JP Morgan | Neutral |
| 2022-05-31 | 開始されました | Jefferies | Buy |
| 2022-05-31 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 開始されました | Wells Fargo | Overweight |
| 2022-05-11 | 開始されました | Cowen | Outperform |
すべてを表示
Bausch Lomb Corp (BLCO) 最新ニュース
Why Bausch + Lomb (BLCO) Just Strengthened Something Beyond Earnings - Insider Monkey
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript - The Globe and Mail
Bausch + Lomb Corp stock (CA07174N1090): Why Google Discover changes matter more now - AD HOC NEWS
10 High Growth Canadian Stocks to Buy Now - Insider Monkey
Bausch + Lomb (NYSE:BLCO) Rating Increased to Buy at Wall Street Zen - MarketBeat
Bausch + Lomb Corporation - Baystreet.ca
Used contacts and lens packs add up: 725,000 pounds recycled - Stock Titan
Bausch & Lomb Legal Chief Sees Pay Dip To $3.6M In 2025 - Law360
Form 8-KCurrent report - ADVFN
Tudor Investment Corp ET AL Makes New Investment in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Opens with a 5.46% Gain, Outperforming S&P 500 - Markets Mojo
BLCO SEC FilingsBausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Bausch & Lomb Corp SEC Filing - Stock Titan
Bausch + Lomb (NYSE: BLCO) seeks approval to expand equity plan and elect board - Stock Titan
Bausch + Lomb Corporation Receives FDA 510(k) Clearance For Bi-Blade+ Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update - marketscreener.com
Bausch + Lomb Corp stock: Eye health innovation drives undervaluation debate - AD HOC NEWS
Bausch + Lomb receives FDA clearance for surgical device - Investing.com
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update - Business Wire
Bausch Lomb (NYSE:BLCO) Eye Health Story Gains Attention On Nyse Composite Today - Kalkine Media
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16.34 - 富途牛牛
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
A Look At Bausch + Lomb (NYSE:BLCO) Valuation As ASCRS Presentations Highlight Eye Health Portfolio - simplywall.st
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe - ChartMill
BLCO: Evercore ISI Group Adjusts Price Target While Maintaining Rating | BLCO Stock News - GuruFocus
Evercore Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $17 - 富途牛牛
Bausch + Lomb Corporation (BLCO) stock price, news, quote and history - Yahoo Finance Singapore
Dry eye and cataract data lead Bausch + Lomb's 45-study ASCRS lineup - Stock Titan
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & SuppliesSpecialty Stocks - Yahoo! Finance Canada
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Should Positive ELIOS Glaucoma Trial Results Require Action From Bausch + Lomb (BLCO) Investors? - simplywall.st
Bausch + Lomb to webcast Q1 results and business update April 29 - Stock Titan
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29 - Yahoo Finance
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for I - AD HOC NEWS
Tudor Investment Corp ET AL Takes $2.25 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback - Yahoo Finance
Bausch And Lomb (NYSE:BLCO) Shares Draw Eyes Across Nyse Composite Today - Kalkine Media
3 Reasons BLCO is Risky and 1 Stock to Buy Instead - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - The Motley Fool
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $19 - 富途牛牛
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System - Intellectia AI
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma - BioSpace
Bausch + Lomb reports positive glaucoma trial results for ELIOS - Investing.com
Glaucoma laser left 82% of patients medication-free in U.S. trial - Stock Titan
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Market Shifts and Deb - AD HOC NEWS
RBC reiterates Bausch & Lomb stock rating on DED rival delay - Investing.com Australia
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
RBC reiterates Bausch & Lomb stock rating on DED rival delay By Investing.com - Investing.com South Africa
Bausch Lomb Corp (BLCO) 財務データ
収益
当期純利益
現金流量
EPS
1.86%
1.85%
大文字化:
|
ボリューム (24 時間):